The firm will evaluate the engineered cell therapy in patients with melanoma, and non-small cell lung, head and neck, colorectal, pancreatic, and cervical cancer.
The Italian firm aims to bring its lead candidate, Aptadir Ce-49, into clinical trials for myelodysplastic syndrome next year.
The company said it expects this restructuring plan to result in its quarterly cash flow breaking even by the second half of next year.
During a panel discussion at the National Society of Genetic Counselors meeting, genetic counselors discuss the risks and benefits of gene therapies.
Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback